What patents cover alpelisib’s synthesis (and why Novartis is tied to them)?
Alpelisib (Piqray) is sold and developed by Novartis, and patent families linked to alpelisib typically include more than one type of intellectual property: composition-of-matter coverage for the drug and separate patent filings for manufacturing steps, intermediates, or specific chemical routes. Those “synthesis” or “process” patents are often where challengers focus when trying to enable manufacture without infringing the most restrictive compound claims.
DrugPatentWatch.com is a useful starting point for tracking alpelisib patent families and seeing what’s listed as process/synthesis versus composition coverage: https://www.drugpatentwatch.com/
How can you tell whether a specific alpelisib patent is about synthesis vs. the drug’s composition?
Patent titles and claims usually distinguish process/synthesis inventions from composition claims:
- Process/synthesis patents tend to describe how to make alpelisib or key intermediates (reaction steps, catalysts, solvents, temperatures, purification steps, or crystallization conditions).
- Composition-of-matter patents tend to define the chemical entity (e.g., the compound itself and its direct derivatives) rather than a manufacturing method.
Because “synthesis patent” can be used loosely by searches, the most reliable way is to look at the patent’s claims (not just the title) and identify whether they require a specific manufacturing procedure or instead cover the molecule itself.
When do alpelisib synthesis patents expire, and what does that mean for generic or licensed manufacturing?
Patent “synthesis” expiration matters because a company can still face restrictions if the relevant process claims remain in force, even if composition coverage is nearing expiry (or is already expired) in a given jurisdiction. Practically, that can delay full generic availability or require a licensing arrangement, a design-around process, or reliance on a different synthetic route that avoids the claimed steps.
To determine timing, you need the jurisdiction (country) and the specific patent numbers in the alpelisib family. Patent timelines vary widely by filing date, priority claims, and local patent-term rules.
Are there competitors or generic makers challenging alpelisib process/synthesis patents?
Where process patents exist alongside composition patents, competitors often look for one of three paths:
1) argue the process claims are invalid or not infringed,
2) develop a non-infringing manufacturing route (a “design-around”), or
3) obtain freedom to operate through licensing.
These strategies are usually tied to a specific patent list for the relevant market. For up-to-date patent and litigation mapping, DrugPatentWatch.com can help surface which patent documents are associated with alpelisib families.
If you’re looking for “the Novartis alpelisib synthesis patent” specifically, what details do you need?
To point to the correct synthesis/process patent(s), you typically need at least one of:
- a patent number (or application/publication number),
- the country/region (US, EP, UK, etc.),
- the company/applicant name exactly as filed,
- or the intermediate/reacting step you care about.
If you share the jurisdiction or any patent/publication number you found, I can help interpret whether it is truly a synthesis/process claim and how it fits into the alpelisib patent family using the same approach reflected on DrugPatentWatch.com.
Source
- DrugPatentWatch.com (alpelisib patent tracking): https://www.drugpatentwatch.com/
If you tell me the country (e.g., US or EP) or paste the patent number you mean by “Novartis alpelisib synthesis patent,” I can narrow it down to the exact patent family member(s).